Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7266792 | 0.98 | TAAR1 (0.61) | TAAR1SLC6A2CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL29037325 | 0.90 | TAAR1 (0.52) | TAAR1SLC6A2CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL5308339 | 0.88 | SLC6A2 (0.55) | TAAR1SLC6A2CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL152994 | 0.88 | TAAR1 (0.50) | TAAR1SLC6A2CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL8866151 | 0.86 | BLM (0.56) | TAAR1SLC6A2CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL8867124 | 0.86 | SLC6A2 (0.60) | TAAR1SLC6A2CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL28073136 | 0.86 | TAAR1 (0.53) | TAAR1SLC6A2CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL5305664 | 0.86 | SLC6A2 (0.55) | TAAR1SLC6A2CYP2D6LMNASMN1; SMN2 | |
| SCHEMBL8865764 | 0.86 | SLC6A2 (0.53) | TAAR1SLC6A2CYP1A2CYP2C19CYP2C9 | |
| Maleic Acid SCHEMBL7267609 | 0.86 | TAAR1 (0.53) | TAAR1SLC6A2CYP1A2CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007017652-A2 | ARYLAKYLAMINES FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | claimed |
| CN-1200702-C | Use of NMDA antagonists for the treatment of irritable bowel syndrome | ASTRA ZENECA AG (SE) | 2005-05-11 | — | — | CN | claimed |
| EP-1073430-B1 | USE OF NMDA ANTAGONISTS AND/OR SODIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ASTRAZENECA AB (SE) | 2004-07-28 | — | — | EP | claimed |
| EP-1073431-B1 | USE OF NMDA ANTAGONISTS FOR TREATMENT OF IRRITABLE BOWEL SYNDROME | ASTRAZENECA AB (SE) | 2004-07-07 | — | — | EP | claimed |
| CN-1307471-A | Use of NMDA antagonists for treatment of irritable bowel syndrome | ASTRA ZENECA AG (SE) | 2001-08-08 | — | — | CN | claimed |
| US-6221887-B1 | USE OF REMACEMIDE OR A METABOLITE OF REMACEMIDE | ASTRAZENECA AB (SE) | 2001-04-24 | — | — | US | claimed |
| EP-1073431-A1 | USE OF NMDA ANTAGONISTS FOR TREATMENT OF IRRITABLE BOWEL SYNDROME | AstraZeneca AB (SE) | 2001-02-07 | — | — | EP | claimed |
| EP-1073430-A1 | USE OF NMDA ANTAGONISTS AND/OR SODIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | AstraZeneca AB (SE) | 2001-02-07 | — | — | EP | claimed |
| WO-1999055322-A9 | USE OF NMDA ANTAGONISTS AND/OR SODIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ASTRAZENECA UK LTD (GB) | 2000-07-27 | — | — | WO | claimed |
| WO-1999055323-A1 | USE OF NMDA ANTAGONISTS FOR TREATMENT OF IRRITABLE BOWEL SYNDROME | ASTRAZENECA AB (SE) | 1999-11-04 | — | — | WO | claimed |
| WO-1999055322-A1 | USE OF NMDA ANTAGONISTS AND/OR SODIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ASTRAZENECA AB (SE) | 1999-11-04 | — | — | WO | claimed |
| EP-0356035-B1 | Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties | ASTRA AB (SE) | 1996-03-13 | — | — | EP | claimed |
| WO-1995031986-A1 | COMBINATION PRODUCT OF DICHLOROACETIC ACID AND AN NMDA ANTAGONIST | ASTRA AKTIEBOLAG (SE) | 1995-11-30 | — | — | WO | claimed |
| US-5430044-A | Arylalkyl-amines and -amides having anticonvulsant and neuroprotective properties | FISONS CORPORATION (GB) | 1995-07-04 | — | — | US | claimed |
| US-20250129112-A1 | Novel Prodrugs Derived from Nicotinic Acid and Ribose | MITOPOWER, INC. | 2025-04-24 | — | — | US | disclosed |
| US-12178827-B2 | Nicotinyl riboside compounds and their uses | MITOPOWER LLC (US) | 2024-12-31 | — | — | US | disclosed |
| US-12168673-B2 | Prodrugs derived from nicotinic acid and ribose | MITOPOWER, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| WO-1989006646-A1 | 2-AMINO ACETAMIDE DERIVATIVES | FISONS CORPORATION (US) | 1989-07-27 | — | — | WO | disclosed |
| EP-0279937-A1 | 2-Aminoacetamide derivatives | FISONS CORPORATION (US) | 1988-08-31 | — | — | EP | disclosed |
| EP-0278089-A2 | 2-Azacyclocarboxamide derivatives | FISONS CORPORATION (a Massachusetts corporation) (US) | 1988-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129112-A1 | Novel Prodrugs Derived from Nicotinic Acid and Ribose | NME4, NADK, NNT | TAAR1 2998/4885SLC6A2 361/4885CYP1A2 1198/4885 |
| US-12168673-B2 | Prodrugs derived from nicotinic acid and ribose | NNT, NME4, NADK | TAAR1 3282/4885SLC6A2 389/4885CYP1A2 857/4885 |
| US-12178827-B2 | Nicotinyl riboside compounds and their uses | NADK, NNT, NAMPT | TAAR1 3435/4885SLC6A2 835/4885CYP1A2 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.